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Abstract 
Background: Previous data show that serotonin 2C (5-HT2C) and cannabinoid 1  (CB1) receptors have a role in the 
modulation of sleep–wake cycle. Namely, antagonists on these receptors promoted wakefulness and inhibited rapid 
eye movement sleep (REMS) in rodents. The interaction of these receptors are also present in other physiological 
functions, such as the regulation of appetite. Blockade of 5-HT2C receptors modulat the effect of  CB1 receptor antago-
nist, presumably in consecutive or interdependent steps. Here we investigate, whether previous blockade of 5-HT2C 
receptors can affect  CB1 receptor functions in the sleep–wake regulation.
Results: Wistar rats were equipped with electroencephalography (EEG) and electromyography (EMG) electrodes. 
Following the recovery and habituation after surgery, animals were injected intraperitoneally (ip.) with SB-242084, 
a 5-HT2C receptor antagonist (1.0 mg/kg) at light onset (beginning of passive phase) followed by an injection with 
AM-251, a  CB1 receptor antagonist (5.0 or 10.0 mg/kg, ip.) 10 min later. EEG, EMG and motor activity were analyzed 
for the subsequent 2 h. Both SB-242084 and AM-251 increased the time spent in active wakefulness, while decreased 
the time spent in non-REMS and REMS stages in the first 2 h of passive phase. In combination, the effect of the agents 
were additive, furthermore, statistical analysis did not show any interaction between the effects of these drugs in the 
modulation of vigilance stages.
Conclusions: Our results suggest that 5-HT2C receptor blockade followed by blockade of  CB1 receptors evoked addi-
tive effect on the regulation of sleep–wake pattern.
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Background
The serotonin (5-HT) and the endocannabinoid (eCB) 
systems show clear interaction in the regulation of vari-
ous physiological functions, like anxiety and depression 
[1–3], coping with stress [4], fear extinction [5] and in 
the regulation of appetite [6, 7]. The 5-HT system has 
a well-known role in the sleep–wake regulation as well. 
Serotonergic neurons fire most actively during wakeful-
ness, decrease their activity rate during non rapid eye 
movement sleep (non-REMS) and fall silent during rapid 
eye movement sleep (REMS) [8]. Several data support 
that the  eCBs and the  cannabinoid 1  (CB1) receptors 
also affect the circadian rhythmicity and the sleep–wake 
cycle. The eCBs might participate in the sleep promotion 
by increasing the time spent in non-REMS and REMS, 
while reducing wakefulness [9]. At the same time, consid-
ering the connection between the 5-HT and the eCB sys-
tems in the sleep–wake regulation, only a few studies can 
be found in the literature. The increase in the time spent 
in slow wave sleep (SWS) by oleamide (a cannabimimetic 
molecule) was prevented by 5-HT reuptake inhibitors 
such as fluoxetine or fenfluramine, but also by agonists 
of the  5-HT1A receptors [10]. Oleamide has also been 
reported to potentiate the action of 5-HT on 5-HT2C 
receptors expressed by Xenopus oocytes [11].
The 5-HT2C and  CB1 receptors are widely distrib-
uted in sleep-modulating areas of the brain, frequently 
located on local inhibitory gamma-aminobutyric acider-
gic (GABAergic) interneurons and glutamatergic neurons 
[12–15]. The GABA release, caused by the activation of 
5-HT2C receptors consequently evokes inhibitory effect 
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on monoaminergic cell groups [13, 16]. Accordingly, the 
role of 5-HT2C receptors has been demonstrated in the 
sleep–wake regulation as well. Administration of the 
5-HT2C agonists, RO 60-0175 and RO 60-0332 increased 
wakefulness and decreased REMS [17]. In line with this, 
mice lacking 5-HT2C receptors had greater amounts 
of wakefulness and spent significantly less time in non-
REMS compared to wild-type controls [18]. Injections of 
ritanserin and ketanserin, possessing 5-HT2A/2C recep-
tor antagonist properties, induced a significant increase 
in SWS and a reduction of both REMS and wakefulness 
in rats [19–23]. However, our previous data show that 
SB-242084, a  highly selective 5-HT2C receptor antago-
nist, promotes wakefulness while decreases both  deep 
slow wave sleep (SWS-2) and REMS [24, 25].
The role of eCBs in the promotion and maintenance of 
sleep have also been supported by genetic studies, namely 
 CB1 receptor knockout mice spent more time in wakeful-
ness compared to their wild-type littermates [26, 27]. The 
 CB1 receptor antagonists SR141716a (rimonabant) and 
AM-251 have been reported to increase wakefulness, 
reduce both non-REMS and REMS in monotherapy [28, 
29], moreover, could block sleep–wake alterations caused 
by eCBs [30].
Exploration of the eCB system is still in the focus of 
research. Up-regulation of the eCB system has been 
found in various disorders like obesity, metabolic disor-
der, osteoporosis, hyperalgesia, intestinal inflammation, 
and in certain cases of impaired fertility in women [14]. 
Thus, investigating the effects of  CB1 receptor blockade 
and its interaction with another neurochemical pathways 
may open a way for new therapeutic application of these 
drugs.
In behavioral studies, more specific interactions have 
been described between  the  CB1 and 5-HT2C recep-
tors. Soria-Gomez et al. [31] have shown that hypopha-
gia induced by oleamide and AM-251 has been blocked 
by SB-242084. Based on the above mentioned findings, 
we aimed to investigate how previous 5-HT2C receptor 
blockade modifies the effect of a  CB1 receptor antagonist 
on the pattern of sleep–wake cycle.
Methods
Animal maintenance
All animal experiments and housing conditions were car-
ried out in accordance with the EU Directive 2010/63/
EU and the National Institutes of Health “Principles of 
Laboratory Animal Care” (NIH Publications No. 85-23, 
revised 1985), as well as specific national laws (the 
Hungarian Governmental Regulations on animal stud-
ies 40/2013). The experiments were approved by the 
National Scientific Ethical Committee on Animal Experi-
mentation. Male, drug and test naïve Wistar rats were 
purchased from Animal Facility (Semmelweis University, 
Budapest, Hungary). Rats (8  weeks old), weighing 300–
330  g at surgery, were kept under controlled environ-
mental conditions (temperature at 21 ± 1  °C and a 12  h 
light–dark cycle starting at 10:00 A.M.). Rats were kept 
three per cage before surgery. Food and water were avail-
able ad  libitum during the whole experiment. All efforts 
were made to minimize pain and suffering of the rats. 
Rats were euthanized with an overdose of anesthetic (hal-
othane) when the experimental procedure was finished.
Surgery
Rats were chronically equipped with electroencephalo-
graphic (EEG) and electromyographic (EMG) electrodes, 
as described earlier [32]. Briefly, stainless steel screw 
electrodes were implanted epidurally over the left frontal 
cortex (2.0  mm lateral and 2.0 anterior mm to bregma) 
and left parietal cortex (2.0  mm lateral and 2.0 anterior 
mm to lambda) for frontoparietal EEG recordings. The 
ground electrode was placed over the cerebellum. EMG 
electrodes (stainless steel spring electrodes embedded 
in silicon rubber; Plastics One Inc., Roanoke, VA, USA) 
were placed into muscles of the neck. Surgery was per-
formed under halothane (2%) anaesthesia (Fluotec 3 
vaporizer) using a Kopf stereotaxic instrument.
Drug administration
SB-242084 [SB, 6-chloro-5-methyl-1-[2-(2-methylpyrid-
3-yloxy)-pyrid-5-yl carbamoyl] indoline] and AM-251 
[AM, N-(Piperidin-1-yl)-5-(4-iodophenyl)-1-(2,4- 
dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide] 
were purchased from Tocris Cookson (Bristol, UK). 
Both compounds were dissolved in vehicle (veh) con-
sisted of 70% PBS (phosphate buffered saline, pH = 7.4), 
20% dimethylsulfoxide and 10% Tween 80. All rats were 
treated with a first (veh or 1 mg/kg SB) and a second [veh 
or 5  mg/kg AM (AM D5) or 10  mg/kg AM (AM D10)] 
intraperitoneal (ip.) injections in 1  ml/kg volume, with 
10 min difference between the injections. Animals (n = 6) 
were treated with  the following treatments, in crosso-
ver design: veh + veh, veh + AM D5, veh + AM D10, 
SB + veh, SB + AM D5, SB + AM D10.
EEG recording
After surgery, rats were kept in a square, glass record-
ing chamber separately. After a 7-day-long recov-
ery period, rats were attached to the EEG system by 
a flexible recording cable and an electric swivel, fixed 
above the cages, permitting free movement of the ani-
mals. In order to habituate the animals to the record-
ing conditions, rats were attached to the EEG system 
7  days before starting the treatments, and were kept 
connected to the system during the whole experiment. 
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To assess motor activity, electromagnetic transduc-
ers were used, in which potentials were generated by 
movements of the recording cable, as described earlier 
[32]. EEG, EMG and motility were recorded during a 
24-h long period, starting at light onset (10:00 A.M.). 
Rats were undisturbed throughout the recordings 
and had free access to standard rodent chow and tap 
water. The signals were amplified (amplification factors 
approximately 5000 for EEG and motor activity, 20000 
for EMG), conditioned by analogue filters (Coulburn 
Lablinc System, USA; filtering below 0.50 Hz and above 
100  Hz at 6  dB/octave), and subjected to analogue to 
digital conversion with a sampling rate of 256 Hz. Data 
were stored on a computer for further analysis.
Sleep scoring
The vigilance stages were classified automatically by 
SleepSign for Animal sleep analysis software (Kissei 
Comtec America, Inc., USA) followed by visual assess-
ment for 4-s periods over 2 h, as described earlier [32]. 
The visual assessment  and scoring were performed 
by an observer blind to the treatments. The vigilance 
stages scored in the present study were the following: 
active wakefulness (AW), the EEG is characterized by 
low-amplitude activity at beta (14–30  Hz) and alpha 
(8–13 Hz) frequencies accompanied by high EMG and 
intense motor activity; passive wakefulness (PW), the 
EEG is characterized by low-amplitude activity at beta 
(14–30  Hz) and alpha (8–13  Hz) frequencies accom-
panied by high EMG activity but minimal or no motor 
activity; light slow wave sleep (SWS-1), high-voltage 
slow cortical waves (0.5–4  Hz) were interrupted by 
spindles (6–15 Hz) accompanied by reduced EMG and 
no motor activity; deep slow wave sleep (SWS-2), there 
were continuous high-amplitude slow cortical waves 
(0.5–4  Hz) with reduced EMG and no motor activ-
ity; intermediate stage of sleep (IS), a brief stage just 
prior to REMS and sometimes just after it, character-
ized by unusual association of high-amplitude spindles 
(mean 12.5 Hz) and low-frequency (mean 5.4 Hz) theta 
rhythm; rapid eye movement sleep (REMS), low-ampli-
tude and high-frequency EEG activity with regular 
theta waves (5–9 Hz) were accompanied by silent EMG 
and motor activity with occasional twitching. SWS-1 
and SWS-2 sleep stages together create the non-REMS 
stage. The following parameters were calculated (1–2 h 
following treatments): total time spent in each vigilance 
stage (AW, PW, SWS-1, SWS-2, REMS, IS); the occur-
rence of the first REMS period (REMS latency). An 
episode of any vigilance stage was defined as an item 
lasting at least 4 s and not interrupted by any other vig-
ilance stage for longer than 4 s.
Statistical analysis
For statistical analysis STATISTICA 7.0 (Statsoft Inc., 
Tulsa, OK, USA) software was used. Data were ana-
lyzed by two alternative statistical approaches, the con-
clusions were drawn based on these two methods. Sleep 
parameters of the treatment groups were evaluated by 
two-way analysis of variance (ANOVA) with two fac-
tors: pretreatment [veh or SB] and treatment [veh or 
AM DX (X = 5 or 10 mg/kg dose)] and their interaction. 
We also performed one-way ANOVA tests in each vigi-
lance stage including the 6 treatment groups. In case of 
significant main effects of the one-way ANOVA  tests, 
the difference between the groups was investigated by 
Dunnett’s post hoc analysis (indicated on the  figures). 
In contrast to two-way ANOVA, the post hoc methods 
compare the means of groups, with the special case of 
Dunnett’s test, that compare all  treated groups to the 
control  one. The two methods are complementary to 
each other. The two-way ANOVA method is more pow-
erful but the Dunnett’s method is based on fewer statis-
tical assumptions. In both statistical tests p values less 
than 0.05 (p < 0.05) were defined as statistically signifi-
cant. Data on the figures are presented as mean ± SEM.
Results
SB‑242084 and AM‑251 showed additive active 
wake‑promoting effect
With regard to wakefulness, SB-242084 and AM-251 
treatments showed additive effect to increase the time 
spent in AW. However, post hoc analysis did not reveal 
significant effect of SB or AM D5 in mono-treatments, 
compared to the veh + veh control group. The AW-pro-
moting effects of the drugs were statistically significant 
when administered simultaneously. The effect of  AM 
D10 was significant in mono-treatment and in com-
bination with SB as well (Fig.  1a). Two-way ANOVA 
showed significant effect of both SB and AM D5 
(F1,20 = 6.777; p = 0.0170 and F1,20 = 5.482; p = 0.0297, 
respectively) on the time spent in AW, but we did not 
find interaction between the two agents. Regarding the 
combination of SB with the higher AM dose, two-way 
ANOVA showed a tendency of SB to increase AW, a 
significant effect of AM D10 (F1,20 = 3.002; p = 0.0985 
and F1,20 = 7.263; p = 0.0139, respectively) on the 
time spent in AW and a trend in the interaction effect 
(F1,20 = 3.025; p = 0.0974).
Regarding PW, we did not find any significant effect 
of SB, AM D5 or AM D10, or their combination in 
post hoc analysis or with  two-way ANOVA statistics 
(Fig. 1b).
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SB‑242084 and AM‑251 caused additive reduction in slow 
wave sleep
In SWS-2 stage, the post hoc analysis after  signifi-
cant one-way ANOVA showed a trend effect of SB 
(p = 0.0683), although AM D5 treatment did not cause 
any significant effect. However, AM D10 mono-treat-
ment showed a significant decrease in the time spent in 
SWS-2 compared to the veh + veh group. At the same 
time, the combination of SB with AM D5 or AM D10 
doses showed a significant decrease in time spent in 
SWS-2 in both cases. Interestingly, this effect seemed 
to be stronger in case of the SB + AM D5 combina-
tion (Fig.  1d). Two-way ANOVA statistics revealed a 
significant effect of both the pretreatment with SB 
(F1,20 = 11.25; p = 0.0032), and the treatment with AM 
D5 (F1,20 = 4.402; p = 0.0488). However, we did not find 
any interaction between the treatments (F1,20 = 0.1509; 
p = 0.7018). AM D10 treatment also showed a trend 
effect (F1,20 = 4.305; p = 0.0511) in two-way ANOVA, 
but no interaction was found between the SB and AM 
D10 treatments.
Regarding SWS-1, SB significantly decreased the time 
spent in this stage (pretreatment effect: F1,20 = 6.648; 
p = 0.0179), but we did not find any significant treatment 
effect of AM D5 or AM D10 (Fig. 1c).
Taken together, in monotherapy the  time spent in 
SWS-2 was decreased by SB, AM D5 and AM D10 as 
well, while the  time spent in SWS-1 was reduced by SB 
Fig. 1 The effects of SB-242084 (SB, 1 mg/kg ip.) and AM-251 (AM D5, 5 mg/kg ip. and AM D10, 10 mg/kg ip.) treatments on the time spent in a 
active wakefulness (AW); b passive wakefulness (PW); c light slow wave sleep (SWS-1); d deep slow wave sleep (SWS-2); e rapid eye movement 
sleep (REMS); f intermediate stage of sleep (IS) in the summarized first 2 h of the passive phase. Data are presented as mean ± SEM of the 6 animals. 
*p < 0.05, **p < 0.01, ***p < 0.001 compared to the veh + veh control group (Dunnett’s post hoc comparison)
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only. In combination, SB and AM showed a  significant 
decrese in SWS-2 by post hoc results, compared to con-
trol. Both AM D5 and AM D10 treatments were capable 
to increase the effect of SB, suggesting additive effect of 
the drugs on reducing SWS-2 only.
SB‑242084 and AM‑251 suppressed REMS and IS
Regarding the post hoc tests after  significant one-way 
ANOVA, SB, AM D5 and AM D10 showed significant 
REMS-reducing effect in both mono-treatment and in 
combinations (Fig.  1e). According to two-way ANOVA, 
both SB and AM D5 treatments significantly decreased 
the time spent in REMS (F1,20 = 10.48; p = 0.0041 and 
F1,20 = 7.868; p = 0.0109, respectively), but we did not find 
any interaction effect (F1,20 = 1.646; p = 0.2141). Similarly, 
significant pretreatment and treatment effects were seen 
in two-way ANOVA, when combining SB with AM D10 
(F1,20 = 5.866; p = 0.0251 and F1,20 = 17.58; p = 0.0004, 
respectively) and an interaction effect (F1,20 = 6.964; 
p = 0.0157) as well.
Regarding REMS latency, two-way ANOVA revealed 
that, both SB and AM D5 treatment significantly 
increased REMS latency (SB effect: F1,19 = 12.35; 
p = 0.0023; AM effect: F1,19 = 9.045; p = 0.0072). At the 
same time, in the SB + AM D10 combination, two-way 
ANOVA showed a significant treatment effect of AM 
D10 (F1,15 = 6.265; p = 0.0244), moreover, an interaction 
between the two agents (F1,15 = 9.732; p = 0.0070).
Regarding the time spent in IS, post hoc tests after 
one-way ANOVA showed, that AM D10 reduced IS sig-
nificantly compared to veh + veh control group, while 
AM D5 produced a similar reduction when combined 
with SB (Fig. 1f ). Two-way ANOVA showed a significant 
effect of SB in combination with AM D5 (F1,20 = 10.82; 
p = 0.0037). However, in the SB + AM D10 combina-
tion, AM D10 showed significant effect alone and an 
interaction effect as well (F1,20 = 6.532; p = 0.0188 and 
F1,20 = 6.975; p = 0.0157, respectively).
To sum up, both SB and AM in both doses tended to 
decrease REMS. However, while the effect of AM D5 
seemed to be added to the REM-suppressing effect of SB, 
AM D10 could not produce this additive effect, despite 
decresing REMS alone. The cause of this can be that the 
maximal REMS-decreasing effect was already reached by 
AM D10 in mono-treatment, thus, further enhancement 
of this effect was not possible by the combined treatment.
Discussion
Our study confirms, in agreement with previous findings, 
that the combination of 5-HT2C and  CB1 receptor antag-
onists increases wakefulness, while decreases the time 
spent in non-REMS and REMS stages as a result of an 
additive effect of the agents. Based on two-way ANOVA, 
both SB and AM influenced AW, SWS-2, REMS and IS 
parameters and SB modulates SWS-1 too. The effect 
of AM was different in D5 and D10 doses. In 10 mg/kg 
dose AM increased AW, and decreased the time spent in 
SWS-2, REMS and IS, however, when applied in 5 mg/kg 
it reduced REMS only. In combination with SB, the effect 
of AM D5 and D10 was similar, increasing the time spent 
in AW, while reducing SWS-2 and REMS. The additive 
effect of SB and AM was obvious in the SB + AM D5 
combination. However, based on interaction effects of 
the SB + AM D10 combination in the time spent in AW 
and SWS-2 parameters, the additive effect was weaker in 
this combination.
Neurochemical and electrophysiological studies have 
found that the role of 5-HT in the sleep–wake regula-
tion is promoting wakefulness and inhibiting REMS [33, 
34]. Regarding 5-HT2C receptors, their mRNA has been 
found in the cholinergic pedunculopontine and latero-
dorsal tegmental nuclei (PPT/LDT) [12]. These neurons 
fire most rapidly during wakefulness and REMS, and 
most slowly during non-REMS [35]. The  5-HT2C recep-
tors have been found in the dorsal raphe nuclei (DRN) as 
well [13] and are expressed mainly by inhibitory GABAe-
rgic interneurons, but also by excitatory glutamatergic 
neurons [36]. The exact mechanism of the elevation of 
the amount of wakefulness  and the suppression of both 
non-REMS and REMS caused by the blockade of 5-HT2C 
receptors is still unclear, but these effects may be par-
tially mediated by the suppressed activity of GABAer-
gic neurons in the DRN. This decrease in the inhibitory 
influence of DRN may lead to an increase in the mono-
aminergic cell firing, consequently inducing an inhibition 
on the PPT/LDT neurons.
The role of eCBs has also been demonstrated in the 
regulation of the sleep–wake cycle, based on the finding 
that these bioactive lipids reduced wakefulness and pro-
moted non-REMS and REMS [9]. In line with this,  the 
 CB1 receptor antagonists SR141716a and AM-251 pre-
sented the opposite effects, promoting wakefulness and 
decreasing both non-REMS and REMS activity [28, 
29]. Intracerebroventricular administration of the eCB 
anandamide (ANA) during the lights-on period caused 
diminution in wakefulness, while increased non-REMS 
and REMS in rats. This effect was more evident when 
ANA was injected  directly into the PPT nucleus, and 
SR141716a prevented this effect [37, 38]. Experimental 
evidence indicates that the activation of the  CB1 recep-
tors promotes the release of acetylcholine (ACh) in corti-
cal and hippocampal areas [39]. Therefore, the blockade 
of  CB1 receptors in local GABAergic and glutamatergic 
networks might influence the release of ACh in the PPT/
LDT and in the basal forebrain inducing wakefulness and 
reducing sleep.
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With regard to the regulation of REMS by cannabi-
noids, infusion of 2-arachidonoylglycerol (2-AG) into 
the lateral hypothalamus caused a massive increase of 
REMS, while AM-251 was able to block this effect [40]. 
In the hypothalamic regulation of the sleep–wake cycle, 
WIN 55,212-2, a potent  CB1 receptor agonist has been 
shown to depolarize melanin-concentrating hormone 
(MCH) neurons in the hypothalamus in  vitro [41]. In 
line with this, 2-AG activates these neurons in  vivo, 
thereby increasing REMS [42]. MCH neurons promote 
non-REMS and REMS, by showing their maximal fir-
ing rate during REMS, moderately firing during non-
REMS, and being almost silent during wakefulness 
[43]. These findings suggest that eCBs also influence 
the hypothalamic regulation of sleep acting on MCH 
neurons. Correlation between the amount of REMS 
and neuronal (Fos) activation of the MCH neurons 
during rebound sleep after selective REMS depriva-
tion has also been demonstrated by Kitka et al. [44]. In 
rats, SR141716a has also been shown to prevent REMS 
rebound following selective REMS deprivation [45].
In our study, SB with the lower dose of AM (5 mg/kg) 
caused a clear additive effect in AW, SWS-2 and REMS 
parameters, but these effects were weaker when SB was 
combined with AM D10. This phenomenon may be due 
to  various  reason. Several findings suggested a dose-
dependent pharmacological effect of WIN55,212-2 on 
the  CB1 receptors of inhibitory and excitatory neurons in 
the hippocampus of mice, namely the inhibitory synaptic 
transmission was more sensitive to the effect of cannabi-
noid receptor modulator, than the excitatory neurotrans-
mission [46, 47]. Another potential reason can be, that, 
in terms of  CB1/CB2 receptor selectivity, AM-251 simi-
larly to its structural analog SR141716a, is a  CB1 recep-
tor selective compound in nanomolar concentration, but 
in higher doses the effect is not  CB1 specific. Binding 
experiments showed, that in micromolar concentration, 
SR141716a and AM-251 can interact on both transient 
receptor potential vanilloid type 1 and adenosine A1 
receptors [48–51]. Thus, the effect of the higher dose of 
AM-251 on other cell types or receptors might explains, 
why this dose attenuated the additive effect. In line with 
our findings, there is another example in the literature, 
where synergistic or additive effects of  CB1 and 5-HT2C 
receptor functions showed  dependency on the dose-
ratios of the applied drugs. Ward et  al. have measured 
the effect of SR141716a, meta-chlorophenylpiperazine 
(mCPP, a 5-HT2C receptor agonist) and their combina-
tion on motivation to consume a palatable drink in mice. 
When combined in 1:1 and 2:1 dose ratios, SR and mCPP 
produced significant synergistic effect, while in 3:1 ratio 
their interaction led to additive effect in attenuation of 
motivation to consume palatable drink [6].
Although, the additive effect of SB treatment with the 
higher dose of AM (10  mg/kg) was weaker, AM D10, 
similarly to AM D5 exerted its effect after SB-242084 
treatment as well. Therefore, we can conclude that 
although the two drugs can produce additive interac-
tion in a given dose, they might also act independently 
from each other. This is in agreement with literature 
data (see above) reporting that both SB and AM evoke 
their sleep–wake modulating effect by influencing 
PPT/LDT neurons, however, can also exert their effect 
on different ways. SB modulates DRN neurons in the 
brainstem leading to the inhibition of PPT/LDT neu-
rons firing, whereas AM influences local GABAergic 
and glutamatergic networks within the PPT/LDT exert-
ing a more direct effect on these neurons. Luppi et al. 
[52] have also emphasized the role of local GABAergic 
and glutamatergic networks over the aminergic-cho-
linerg projections in REMS regulation. AM modulates 
the hypothalamic MCH neurons as well, but until 
nowadays no data is available investigating the effect 
of SB on this neuron population. Thus, the MCH neu-
ron population might be the other target on which AM 
can exert its effect independently from SB treatment.
Conclusion
Taken together, blockade of the 5-HT2C and  CB1 recep-
tors influences the sleep–wake pattern in a similar way 
by inducing wakefulness and suppressing both  non-
REMS and REMS. Our findings reinforce the role 
of eCB and serotonergic system in the regulation of 
sleep–wake behavior. These data also suggest that 
5-HT2C receptor blockade followed by blockade of  CB1 
receptors evoke additive effects on the regulation of 
sleep–wake pattern that may provide additional infor-
mation regarding their interaction in the central nerv-
ous system.
As the drugs were administered intraperitoneally, and 
not into specific nuclei of the brain involved in regu-
lation of vigilance, we cannot exclude the influence of 
several other factors on their interaction in the regula-
tion of sleep–wake cycle.
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acidergic; ip.: intraperitoneally; IS: intermediate stage of sleep; MCH: melanin-
concentrating hormone; mCPP: meta-chlorophenylpiperazine; non-REMS: 
non rapid eye movement sleep; PPT/LDT: pedunculopontine and laterodorsal 
tegmental nuclei; PW: passive wakefulness; REMS: rapid eye movement sleep; 
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SB: SB-242084; SWS: slow wave sleep; SWS-1: light slow wave sleep; SWS-2: 
deep slow wave sleep.
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